A. Oton

发表

Lung cancer in elderly patients: an analysis of the surveillance, epidemiology, and end results database.

Taofeek K Owonikoko, T. Owonikoko, S. Ramalingam, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Significant Downregulation of Platelet Gene Expression in Metastatic Lung Cancer

M. Weyant, T. Phang, B. Gao, 2010, Clinical and translational science.

Sequential therapy with ramucirumab and/or checkpoint inhibitors for non-small-cell lung cancer in routine practice.

M. Mahoui, Xiaohong Li, A. Oton, 2019, Future oncology.

Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy

Edward S. Kim, A. Wozniak, B. Levy, 2018, The Patient - Patient-Centered Outcomes Research.

LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

M. Kris, M. Socinski, J. Soria, 2014 .

Proteomics analysis in post‐transplant lymphoproliferative disorders

A. Leontovich, I. Ghobrial, X. Leleu, 2008, European journal of haematology.

Clinical and pathological prognostic markers for survival in adult patients with post-transplant lymphoproliferative disorders in solid transplant

A. LaCasce, K. Foon, I. Ghobrial, 2008, Leukemia & lymphoma.

MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study

D. Ettinger, M. Kris, M. Socinski, 2017 .

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

P. Bunn, R. Doebele, D. Camidge, 2010, Lung cancer.

A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer

F. Hirsch, W. Franklin, M. Varella‐Garcia, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oncogene status predicts patterns of metastatic spread in treatment‐naive nonsmall cell lung cancer

P. Bunn, W. Franklin, M. Varella‐Garcia, 2012, Cancer.

EGFR Mutations in Latinos From the United States and Latin America

G. Giaccone, S. Steinberg, M. Raffeld, 2016, Journal of Global Oncology.

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed

W. Franklin, M. Varella‐Garcia, R. Doebele, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

The histone deacetylase inhibitor, PXD101, potentiates bortezomib‐induced anti‐multiple myeloma effect by induction of oxidative stress and DNA damage

M. Mapara, C. Belani, Gülsüm Anderson, 2007, British journal of haematology.

MAGE A3 antigen-specific cancer immunotherapeutic.

F. Hirsch, P. Bunn, N. Peled, 2009, Immunotherapy.

Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol

A. Oton, D. Kern, L. Hess, 2017, JMIR research protocols.

Drug wastage and costs to the healthcare system in the care of patients with non-small cell lung cancer in the United States

Ian A. Watson, Xiaohong Li, A. Oton, 2018, Journal of medical economics.

Treatment sequencing for the care of patients with advanced or metastatic non-small cell lung cancer in the United States

Xiaohong Li, A. Oton, C. Molife, 2020, Current medical research and opinion.

Disease and economic burden of surgery in desmoid tumors: a review

Shengfan Zhou, A. Oton, T. Bell, 2023, Expert review of pharmacoeconomics & outcomes research.

Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy

M. Socinski, G. Scagliotti, Michael Thomas, 2020, ESMO Open.

Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015

U. Dafni, C. Vallejos, D. Hong, 2016, ESMO Open.

Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040

Yun Fang, A. Oton, L. Hess, 2017, Journal of medical economics.

Rapid‐onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer

R. Doebele, D. Camidge, M. Rothman, 2012, Cancer.

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients

J. Nieva, S. Ou, P. Bunn, 2013, Cancer.

Factors Associated with Adherence to and Treatment Duration of Erlotinib Among Patients with Non-Small Cell Lung Cancer.

A. Oton, L. Hess, K. Winfree, 2017, Journal of managed care & specialty pharmacy.

Desmoid Tumors: A Comprehensive Review

A. Oton, M. Bektas, Shahnaz Khan, 2023, Advances in therapy.

Comparison of survival for non-small cell lung cancer (NSCLC) between premenopausal and postmenopausal women: An analysis of the National Surveillance, Epidemiology and End Results (SEER) Database.

T. Owonikoko, S. Ramalingam, W. Gooding, 2006, Journal of Clinical Oncology.

Safety Analyses of Pemetrexed-cisplatin and Pemetrexed Maintenance Therapies in Patients With Advanced Non-squamous NSCLC: Retrospective Analyses From 2 Phase III Studies.

G. Scagliotti, C. Gridelli, A. Wozniak, 2017, Clinical lung cancer.